US biotech Amylyx Pharmaceuticals (Nasdaq: AMLX) today revealed it has appointed Camille Bedrosian as its new chief medical officer (CMO).
In this role, Dr Bedrosian will lead global functions in medical affairs, regulatory, safety and pharmacovigilance, biometrics, clinical development, and clinical operations.
Dr Bedrosian brings nearly 30 years of experience addressing unmet medical needs for people with rare and serious diseases through successful clinical and translational research programs, including as CMO at Ultragenyx Pharmaceutical (Nasdaq: RARE), Alexion Pharmaceuticals and Ariad Pharmaceuticals (Nasdaq: ARIA).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze